Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298395 · ClinicalTrials.gov registry record · Phase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis (AD), sponsored by Enveda Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 12
- Study locations
NCT07298395: Recruiting Phase 2 study of Atopic Dermatitis (AD), sponsored by Enveda Therapeutics.
NCT07298395 is a Phase 2 study of Atopic Dermatitis (AD) that is actively recruiting participants, run by Enveda Therapeutics. The registered enrollment target is 64 participants, below the 101-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (37% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07298395, a Phase 2 study of Atopic Dermatitis (AD), is actively recruiting participants, sponsored by Enveda Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug ENV-294 * Return to the clinic for the final study visit at approximately week 16
Primary Outcome
The effectiveness of ENV-294 compared with placebo will be assessed by the percent change in Eczema Area and Severity Index (EASI) score from the start of the study (Baseline) to Week 12 (Day 85). The EASI score measures the extent and severity of atopic dermatitis, with higher scores indicating more severe disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ENV-294
Study Locations (12)
Texas
- Arlington Research Center - Arlington
- Center for Clinical Studies - Houston
- Texas Dermatology and Laser Specialists - San Antonio
California
- Center for Dermatology Clinical Research - Fremont
- TCR Medical Corporation - San Diego
Indiana
- Southern Indiana Clinical Trials - New Albany
- Options Research Group - West Lafayette
Alabama
- Cahaba & Skin Health Center - Birmingham
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Michigan
- Michigan Center for Skin Care Research - Clinton Township
Pennsylvania
- Best Skin Research - Camp Hill
Virginia
- Virginia Dermatology & Skin Cancer Center - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT07298395 shows while recruiting
NCT07298395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 101-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07298395 lists 12 locations in 8 states (Texas, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT07298395 about?
NCT07298395 is a clinical study titled "Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis". The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical pro...
What is the current status of trial NCT07298395?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2025-12-22. Estimated completion is 2026-12.
What conditions does trial NCT07298395 study?
This clinical trial studies the following conditions: Atopic Dermatitis (AD).
What interventions are being tested in trial NCT07298395?
The interventions under investigation include: Placebo (DRUG), ENV-294 (DRUG).
Who is sponsoring clinical trial NCT07298395?
This trial is sponsored by Enveda Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07298395 being conducted?
This trial has 12 study locations across Alabama, Arkansas, California, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING · Phase 1
-
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
RECRUITING · Phase 1
-
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
RECRUITING · Phase 1
-
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI